Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in several investor conferences in September 2020. Key events include the Baird 2020 Global Healthcare Conference on September 9, the Citi 15th Annual BioPharma Virtual Conference on September 10, and the Cantor Virtual Global Healthcare Conference on September 15. CEO Cedric Francois will engage in discussions at these conferences, including a panel on ophthalmology at Citi's event. Live webcasts will be available on the company's website, with replays accessible for 90 days.

WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will participate in the following upcoming investor conferences in September:

• Baird 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 2:35 p.m. ET
• Citi 15^th Annual BioPharma Virtual Conference on Thursday, September 10, 2020 at 9:50 a.m ET and 3:20 p.m. ET
• Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020 at 2:40 p.m. ET

Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat at the Baird 2020 Global Healthcare Conference, an ophthalmology panel discussion titled “Seeing 20/20 in 2020” at the Citi 15th Annual BioPharma Virtual Conference, a fireside chat at the Citi 15th Annual BioPharma Virtual Conference, and a fireside chat at the Cantor Virtual Global Healthcare Conference.

The events will be available via live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. Replays of the webcasts will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. By pioneering targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.

Investor Contact:
Sam Martin / Maghan Meyers
Argot Partners
sam@argotpartners.com / maghan@argotpartners.com
212.600.1902

FAQ

What conferences will Apellis Pharmaceuticals participate in September 2020?

Apellis Pharmaceuticals will participate in the Baird 2020 Global Healthcare Conference on September 9, the Citi 15th Annual BioPharma Virtual Conference on September 10, and the Cantor Virtual Global Healthcare Conference on September 15.

Who is the CEO of Apellis Pharmaceuticals?

The CEO of Apellis Pharmaceuticals is Cedric Francois, M.D., Ph.D.

What is the focus of the presentations by Apellis Pharmaceuticals at these conferences?

The presentations will include discussions on targeted C3 therapies and an ophthalmology panel titled 'Seeing 20/20 in 2020'.

How can I access the live webcasts of Apellis Pharmaceuticals' conference presentations?

Live webcasts can be accessed from the 'Events and Presentations' page on the Apellis Pharmaceuticals website.

When will the replays of the webcasts from Apellis' conferences be available?

Replays of the webcasts will be available for 90 days following the events.